News/Blogs

Three blockbuster medications will lose patent protection in 2025, creating a golden opportunity for plan sponsors to dramatically cut pharmacy costs while maintaining access to quality care. 

The 2025 generic drug landscape isn’t just promising—it’s transformative. With $445 billion in U.S. healthcare savings already achieved through generics and biosimilars in 2023¹, self-insured employers, TPAs, and brokers now stand at the threshold of even greater cost-saving potential. 

The Big Three: Blockbusters Going Generic 

Three high-impact medications will face generic competition in late 2025², each representing a significant portion of current pharmacy spend: 

• Entresto (heart failure treatment): $5.4 billion in 2023 sales 
• Tradjenta (diabetes medication): $1.7 billion in 2023 sales   
• Opsumit (pulmonary hypertension therapy): $1.5 billion in 2023 sales 

Unlike recent years with limited generic launches, 2025 delivers multiple entry points for cost containment. This is particularly valuable as employers struggle to offset rising healthcare expenses. 

Why This Matters: The 90/13 Paradox 

Consider this striking statistic: generic and biosimilar medications represent 90% of all U.S. prescriptions but only 13% of total drug spending². This disparity highlights the extraordinary value proposition of generic medications and the untapped potential when blockbuster drugs lose patent protection. 

Preparing for These Launches

Building on this expanded landscape of generic medication options, plan sponsors can implement several strategies to maximize savings, including:

• Formulary adjustments that prioritize cost-effective alternatives 
• Prior authorization protocols that guide appropriate utilization 
• Strategic benefit design that balances access with affordability 

Rest assured, we’re monitoring these developments closely and will have these approaches ready for implementation when these generics launch. 

Citations:
¹ https://accessiblemeds.org/sites/default/files/2024-09/AAM-2024-Generic-Biosimilar-Medicines-Savings-Report.pdf 
² IPD Analytics, 2025  

Do your clients want a PBM to help track key generic drug launches?
Reach out today to get more information about partnering with us.

About Serve You Rx®   
Serve You Rx is a full-service pharmacy benefit manager (PBM) with unquestionable flexibility and an unwavering commitment to doing what's best for its clients. With a fervent focus on those it serves, including insurance brokers, consultants, third-party administrators, and their clients, Serve You Rx delivers exceptional service and tailored, cost-effective benefit solutions. Independent and privately held for nearly 40 years, Serve You Rx can implement new groups in 30 days or less and say "yes" to a wide variety of viable solutions. Known for its adaptability, quality, and client-centricity, Serve You Rx aims to be a benchmark for better client service.